<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23139">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805556</url>
  </required_header>
  <id_info>
    <org_study_id>206218</org_study_id>
    <secondary_id>AI438-075</secondary_id>
    <nct_id>NCT02805556</nct_id>
  </id_info>
  <brief_title>Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing</brief_title>
  <official_title>Study of the Absolute Bioavailability of BMS-626529 in Healthy Subjects Following Oral Dosing of BMS-663068 and Intravenous Dosing of BMS-626529</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <brief_summary>
    <textblock>
      A phase I absolute bioavailability study of BMS-626529 following oral and intravenous dosing
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The absolute bioavailability of BMS-626529 after single oral (BMS-663068) and single intravenous dosing ([13C]-BMS-626529) by assessing the primary endpoints AUC(inf)</measure>
    <time_frame>up to 11 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of single oral dose of BMS-663068 as determined by medical review of adverse event reports, vital sign measurements, electrocardiograms (ECGs), and results of physical examination and laboratory tests</measure>
    <time_frame>up to 31 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of single intravenous dose of [13C]-BMS-626529 as determined by medical review of adverse event reports, vital sign measurements, electrocardiograms (ECGs), and results of physical examination and laboratory tests</measure>
    <time_frame>up to 31 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Oral dose of BMS-663068 + intravenous dose of [13C]BMS 626529</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of BMS-663068 followed by Single intravenous dose of [13C]BMS 626529</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068</intervention_name>
    <description>Single oral dose of BMS-663068</description>
    <arm_group_label>Oral dose of BMS-663068 + intravenous dose of [13C]BMS 626529</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-626529</intervention_name>
    <description>Single intravenous dose of [13C]BMS 626529</description>
    <arm_group_label>Oral dose of BMS-663068 + intravenous dose of [13C]BMS 626529</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy

          -  BMI 18.0-32.0 kg/m2

          -  Men sexually active with women of childbearing potential must follow instructions for
             contraception for the duration of treatment plus 90 days

          -  Men must refrain from sperm donation for the length of the study and for 90 days

          -  Sign informed consent

        Exclusion Criteria:

          -  Significant medical illness

          -  Tobacco use in the last 12 months

          -  Major surgery within 4 weeks of study administration

          -  Donation of blood within 4 weeks of study administration

          -  Current or recent (within 3 months of study administration) of gastrointestinal
             disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lisburn</city>
        <zip>BT 28 2 RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/pages/home.aspx</url>
    <description>BMS Clinical Trial Education Resource</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 17, 2017</lastchanged_date>
  <firstreceived_date>May 31, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
